Chad Vanderbilt
YOU?
Author Swipe
View article: Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
Genomic features of patients with long-term response (LTR) compared to short term response (STR), non-LTR, and progressive disease (PD) among patients with TMB z-score < 0.
View article: Supplementary Table S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Table S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
List of PD-L1 antibodies used at each site and in the combined cohort.
View article: Supplementary Figure S7 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure S7 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
Univariable and multivariable analyses of association of clinical characteristics with patients achieving complete response (CR) compared to patients not achieving complete response (non-CR).
View article: Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
Genomic features of patients with long-term response (LTR) compared to non-LTR and progressive disease (PD).
View article: Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
Fraction of subclonal non-synonymous mutations among patients with long-term response (LTR), short-term response (STR), and progressive disease (PD).
View article: Supplementary Figure S8 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure S8 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
Distribution of tumor mutational burden (TMB) z-scores among patients with long-term response (LTR), short-term response (STR), and progressive disease (PD).
View article: Supplementary Figure S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
Kaplan-Meier curves of overall survival of patients with long-term response (LTR), short-term response (STR), and progressive disease (PD) from individual sites.
View article: Supplementary Figure S14 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure S14 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
Whole exome sequencing (WES) features of patients with long-term response (LTR), short-term response (STR), and progressive disease (PD).
View article: Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention Open
Figure S2. Microbiome analysis in GBC.
View article: Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
Time on treatment among patients with long-term response (LTR).
View article: Interpretable Multiple Instance Learning for Hematologic Diagnosis from Peripheral Blood Smears
Interpretable Multiple Instance Learning for Hematologic Diagnosis from Peripheral Blood Smears Open
Accurate diagnosis of hematologic malignancies from peripheral blood smears (PBSs) requires integrating cellular morphology and composition across hundreds of white blood cells. Existing approaches primarily automate single-cell classifica…
View article: Genomic characterization of tumor mutational burden-high breast carcinomas
Genomic characterization of tumor mutational burden-high breast carcinomas Open
Tumor mutational burden (TMB) has emerged as a potential surrogate for neoantigen load and an indicator of immune checkpoint (IC)-blockade response; however, its precise significance in breast cancer (BC) is not fully understood. Here, we …
View article: FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity
FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity Open
View article: BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants
BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants Open
Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is a type of T-cell lymphoma arising near textured breast implants. In a Dutch population, a higher prevalence of BRCA1/2 was found in BIA-ALCL. We analyzed the risk of BI…
View article: Single GPU Task Adaptation of Pathology Foundation Models for Whole Slide Image Analysis
Single GPU Task Adaptation of Pathology Foundation Models for Whole Slide Image Analysis Open
Pathology foundation models (PFMs) have emerged as powerful tools for analyzing whole slide images (WSIs). However, adapting these pretrained PFMs for specific clinical tasks presents considerable challenges, primarily due to the availabil…
View article: 120 | DETECTION OF INTRATUMORAL MICROORGANISMS AND THEIR IMPACT ON OUTCOMES IN UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA
120 | DETECTION OF INTRATUMORAL MICROORGANISMS AND THEIR IMPACT ON OUTCOMES IN UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA Open
View article: Figure 3 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Figure 3 from Chromothripsis-Mediated Small Cell Lung Carcinoma Open
Chromothripsis and corresponding cancer gene amplifications and losses. A, Representative Circos plots of SVs and CNAs across the genome by WGS. Outer band shows an ideogram of chromosome positions and cytogenetic bands. Second band…
View article: Data from Chromothripsis-Mediated Small Cell Lung Carcinoma
Data from Chromothripsis-Mediated Small Cell Lung Carcinoma Open
Small cell lung carcinoma (SCLC) is a highly aggressive malignancy that is typically associated with tobacco exposure and inactivation of RB1 and TP53 genes. Here, we performed detailed clinicopathologic, genomic, and transcr…
View article: Figure 1 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Figure 1 from Chromothripsis-Mediated Small Cell Lung Carcinoma Open
Cohort selection and clinicopathologic characteristics. A, Schematic diagram of RB1 and TP53 inactivation (outer doughnut) and smoking status (inner doughnut) in a cohort of 600 consecutive SCLC that underwent tNGS by …
View article: Supplementary Tables S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Tables S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma Open
Supplementary Table S1. Integrated genomic and immunohistochemical results for TP53 and RB1 in aSCLC Supplementary Table S2. Demographic, clinicopathologic and immunohistochemical characteristics: Per patient data Supplementary Table S3. S…
View article: Figure 7 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Figure 7 from Chromothripsis-Mediated Small Cell Lung Carcinoma Open
Outcome and treatment responses. A, Kaplan–Meier analysis of the disease-specific overall survival assessed from the time of diagnosis. B, Pie chart summarizing radiologic treatment response to platinum-based chemotherapy rec…
View article: Figure 6 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Figure 6 from Chromothripsis-Mediated Small Cell Lung Carcinoma Open
Comparison of aSCLC vs. RB1−/TP53− nsSCLC: the dual model of SCLC pathogenesis in never-smokers. A, Lines of evidence for a histogenetic relationship between aSCLC and carcinoids or their progenit…
View article: Supplementary Figures S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Figures S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma Open
Supplementary Figure S1. Detailed morphologic and immunohistochemical findings: Case A01. Supplementary Figure S2. Detailed morphologic and immunohistochemical findings: Case A08. Supplementary Figure S3. Detailed morphologic and immunohis…
View article: Figure 5 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Figure 5 from Chromothripsis-Mediated Small Cell Lung Carcinoma Open
Multisample analysis from all temporally or spatially distinct samples obtained for each patient. A, Conservation of chromothripsis and corresponding amplifications across all samples with available data from individual patients. ^ …
View article: Figure 2 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Figure 2 from Chromothripsis-Mediated Small Cell Lung Carcinoma Open
Mutation and CNA landscape of aSCLC. A, Mutations and CNAs in aSCLC in comparison to the control groups of sSCLC (n = 206) and pulmonary carcinoids (n = 157) analyzed by MSK-IMPACT. OncoPrint summarizing assays perform…
View article: Figure 4 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Figure 4 from Chromothripsis-Mediated Small Cell Lung Carcinoma Open
Chromosomal architecture of chromothripsis and amplifications. A, Integrated SV and CNA analysis in two representative cases confirming the hallmark features of chromothripsis and suggesting formation of ecDNA and micronucleation as…
View article: Increased Risk of Breast Implant-Associated Lymphoma in Carriers of BRCA1/2 Pathogenic Variants: A Cohort and Case-Control Analysis
Increased Risk of Breast Implant-Associated Lymphoma in Carriers of BRCA1/2 Pathogenic Variants: A Cohort and Case-Control Analysis Open
View article: Supplementary Figure S2 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Figure S2 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Kaplan-Meier curve of progression-free survival (PFS) among patients with long-term response (LTR) in the combined cohort.
View article: Supplementary Figure S11 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Figure S11 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Genomic features of patients with long-term response (LTR) compared to short term response (STR), non-LTR, and progressive disease (PD) among patients with TMB z-score < 0.
View article: Supplementary Table S3 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Table S3 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Frequencies of alterations in individual genes among squamous and non-squamous patient groups.